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ABSTRACT
Participant safety and data integrity, critical in trials of
new investigational drugs, are achieved through honest
participant report and precision in the conduct of
procedures. HIV prevention post-trial access studies in
middle-income countries potentially offer participants
many benefits including access to proven efficacious but
unlicensed technologies, ancillary care that often exceeds
local standards-of-care, financial reimbursement for
participation and possibly unintended benefits if
participants choose to share or sell investigational drugs.
This case study examines the possibility that this
combination of benefits may constitute an undue
inducement for some participants in middle-income
countries, where economic challenges are prevalent.
A case study is presented of a single participant in a
cohort of 382 participants who used concealment,
fabrication and deception to ensure eligibility for a post-
trial access study of an unlicensed HIV prevention
technology at potential risk to her health and that of her
fetus. A root cause analysis revealed her desire to access
HIV prevention during an unplanned pregnancy with a
partner whose faithfulness was in question. Researchers
should consider implementation of systems to efficiently
identify similar cases without inconveniencing the
majority of participants
Trial registration number NCT01691768.
INTRODUCTION
Young women in sub-Saharan Africa have a dispro-
portionately high prevalence of HIV,1 making
research on women-initiated and controlled
methods of HIV prevention crucial. Compounded
vulnerability consequent to reduced ability to nego-
tiate safe sex practices with partners,2 3 limited
access to affordable proven HIV prevention therap-
ies4 and economic challenges which undermine
autonomy and increase dependency on others
increase the possibility that participation in these
trials may lead to an increased perception of undue
inducement. This perception could be held by
Research Ethics Committees (RECs), investigators
or other stakeholders, such as community advisory
boards.
Inducement is considered undue only if all of the
following criteria are met: (1) a desirable good is
offered; (2) this offer is large and excessive enough
to be irresistible within the context; (3) the offer
leads to poor judgement in an important decision;
(4) the decision leads to a sufficiently high prob-
ability of harm. Not all inducements are undue.5 6
Independent ethics review is a key element in
ensuring that trials are free of undue inducements.6
However, independent ethics review cannot always
anticipate the unique behaviours of particular
individuals whose circumstances are unknown to
reviewers. Researchers and reviewers cannot restrict
incentives and study benefits because of concerns
that a few individuals might be motivated to pursue
these at any cost. The likelihood of any research
team being able to impact the structural drivers of
HIV risk as they pertain to individual participants
during a study is low, but recognition of these
factors can increase vigilance and application of the
above recommendations to study design and
conduct.6
Motivators for participation in research trials have
been well investigated,7–13 with what constitutes an
undue inducement being debateable.5 6 10 14 15 The
focus is often on financial payments12 13 15 16 and
direct benefits from experimental treatment for the
disease under investigation.8 10 11 A distinction is
made between payment to healthy participants and
those with the condition under investigation,8–10 12 as
well as between research-naïve and research-
experienced populations.7 8 However, research on
inducement has been conducted primarily in high-
income countries, including marginalised populations,
with limited empirical work in low-and-middle-
income countries (LMICs).10
Literature on post-trial access research usually
focuses on legal and ethical obligations of stake-
holders, with some concern for the vulnerability of
patients in treatment trials.17 Post-trial access to
effective, safe HIV prevention modalities, has not
been considered as possible undue inducement for
healthy trial participants who nevertheless have the
condition under study, that is, a high risk of HIV
acquisition, and thus benefit directly (via access to
the modality), and indirectly (via ancillary medical
care), while still contributing to the aspirational
benefit (to society and future participants).18 There
is a dearth of literature on whether having access to
restricted experimental HIV prevention methods
encourages sharing and/or selling of experimental
prevention products with/to others for financial
gain, and whether this creates a further, possibly
undue, inducement to consent to participation in
HIV prevention post-trial access studies.
This case study illustrates and discusses possible
ethical conflicts that may arise for some stake-
holders, including trial participants, in LMICs as
HIV prevention trials increase in number and
access to therapies remain restricted.
BACKGROUND
The Centre for the AIDS Programme of Research
in South Africa (CAPRISA) 004 trial demonstrated
39% reduction in acquisition of HIV infection,
with 54% reduction in women who used tenofovir
gel consistently.2 The CAPRISA 008 trial which
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followed, was an open-label randomised controlled trial to
assess the implementation, effectiveness and safety of 1% teno-
fovir gel provision through family planning services in
KwaZulu-Natal, South Africa.19 This trial had three main goals:
1. to provide post-trial access to tenofovir gel,
2. to develop and assess an implementation model for pre-
exposure prophylaxis (PrEP) provision through family plan-
ning services and
3. to collect additional safety data.
The South African Medicines Control Council approved
CAPRISA 008 only for consenting, research-experienced
CAPRISA 004 participants, who were sexually active, aged
18 years and older, and remained HIV uninfected. The study
was conducted at the CAPRISAVulindlela (rural) and eThekwini
(urban) Research Clinics in KwaZulu-Natal, South Africa and
their neighbouring family planning clinics. CAPRISA 004 parti-
cipants consented to be contacted for other trials at the study
exit visit and contact numbers were readily available to reach
out to volunteers for CAPRISA 008. Of the 786 eligible for
CAPRISA 008, 73(9.3%) were not contactable and 716(91.1%)
were prescreened; 268(37.4%) were excluded either for reasons
of relocation, lack of interest, work/study commitments, HIV
seroconversion, failure to return for enrolment, untraceability at
last known address, pregnancy or planned pregnancy, death and
other reasons. Only 448 (56.9%) were screened with 382
(48.6%) enrolled, with the dropout due to failure to return
within the screening window, HIV seroconversion, lack of sexu-
ally activity, pregnancy and co-enrolment in another trial. The
screening-to-enrolment ratio was 1.7:1. Retention varied
between 90% and 100% for all visits throughout the trial.20
This trial was registered with the South African Department of
Health (reference: DOH-27-0812-4129) and ClinicalTrials.gov
(reference: NCT01691768) on 5 July 2012. The trial was also
approved by the University of KwaZulu-Natal’s Biomedical
REC (BFC273/010).
CAPRISA 008 was nurse-driven to replicate service in the
public sector, with a clinician available for consultation as
needed. Inclusion criteria included a negative urine pregnancy
test and written agreement to initiate non-barrier contraception
at baseline. Urine pregnancy testing was conducted as in
CAPRISA 004, with fresh urine samples collected on the day of
the visit for point-of-care testing in the clinic. A positive urine
pregnancy test during follow-up resulted in cessation of study
product until the outcome was confirmed and the urine preg-
nancy test reverted to negative. Participants remained in
follow-up while pregnant. This criterion was the same for the
efficacy study,2 was part of the contraceptive counselling and
was agreed to by all participants through the informed consent
process. Pelvic examination, including collection of genital
samples, was done at enrolment and every 6 months, or more
frequently if clinically indicated. Genital samples were stored to
assess for markers of safety, risk exposure, product adherence,
potential post-trial assessments of activity against sexually trans-
mitted infections (STIs) and tenofovir resistance.19 Individual
tenofovir levels indicative of product adherence were not ana-
lysed in real time due to prohibitive costs. Adherence during the
study was monitored by clinic and pharmacy staff on an individ-
ual participant basis, matching sexual acts to returns of used and
unused product applicators.19
This case study is of an urban CAPRISA 008 participant, who
apparently, driven by personal circumstances, concealed vital
clinical information, substituted urine samples for pregnancy
testing, underwent trial procedures, received contraception and
study drug, potentially compromising her safety and that of her
fetus. Although product safety had been established in the 004
study, safety had not been demonstrated in pregnancy.
CASE STUDY SUMMARY
A woman aged 25 years with one previous pregnancy (5 years
earlier) was screened early in 2013. At baseline, she perceived
herself at low risk of HIV acquisition, based on her in-depth
knowledge of her partner and the length of their relationship.
The partner was 7 years older than her, and known to be HIV
uninfected. She self-reported her date of birth, as her identity
document was illegible, and supported this with an affidavit
which stated that she was unable to afford a copy of her identity
document, due to her indigent status. She reported that she was
financially dependent on a child grant, intermittent informal
work and variable support from her partner. She reported
irregular menses secondary to depot medroxyprogesterone
acetate (DMPA) in 2012, with the last menses prior to screening
in March 2013. She also reported inconsistent condom use
since cessation of DMPA and agreed to restart contraception. A
stat dose of DMPA was administered and 20 male condoms dis-
pensed. Clinically, her weight was 54 kg, body mass index was
23.7 and her waist circumference was 79 cm. Urine pregnancy
test was negative, with no symptoms or signs on medical history
and general physical examination. In the absence of gynaeco-
logical symptoms, a pelvic examination was not mandated at the
screening visit.
At enrolment she reported a white, inoffensive discharge.
Physical examination was repeated and was normal; pelvic
examination was reported as ‘difficult’, with a poorly visualised
cervix lying posterolaterally and an offensive, frothy white dis-
charge evident. A urine pregnancy test was not repeated, as the
screening test was done less than the protocol mandated 21 days
previously. Genital samples were collected as per protocol.
Following a review of the visit notes and laboratory results, the
clinician provided a script for study product, based on the
reported sexual frequency, which amounted to 10 gels for
1 month (a maximum of two gels to be used within 24 hours,
coitally based).2 The discharge was managed syndromically with
cefixime, metronidazole and doxycycline as per the then
approved South African STI treatment guidelines for non-
pregnant patients.21
During follow-up the participant was seen monthly at four
consecutive visits (relevant findings are reflected in table 1) until
visit 4, when marked abdominal distension was noted by the
research nurse.
The clinician confirmed the pregnancy on abdominal palpa-
tion, noting marked foetal movement, which the participant
claimed not to have felt. The initial and repeat urine pregnancy
tests were both negative and a blood pregnancy test was
requested. Study product was held pending referral for further
investigations. The participant denied knowledge of the preg-
nancy at this stage. An ultrasound and the blood pregnancy test
confirmed pregnancy. The participant accepted the diagnosis but
continued to deny prior knowledge of the pregnancy. A few
months later, she delivered a healthy live male infant via caesar-
ean section, conducted because of a previous caesarean section
and for foetal distress secondary to transient neonatal tachyp-
noea. A bilateral tubal ligation was performed simultaneously at
her request. Paediatric assessment at birth revealed no congenital
abnormalities. At the study exit, the participant’s baby was
noted to be normal with no developmental problems.
In tandem, an extensive root cause analysis was conducted by
the protocol team, to exclude problems regarding pregnancy
test kit integrity and user error. No problems were identified.
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However, it was noted that research nurses in HIV prevention
were relatively inexperienced in conducting obstetric examina-
tions, did not always conduct bimanual palpation of the uterus
and that the method of conducting waist measurement involved
only partial disrobing and thus did not facilitate detection of a
distended abdomen, especially during winter when bulky cloth-
ing is worn.
The clinician requested a private meeting with the participant
at the request of the protocol team to discuss the participant’s
motivation for her decisions and actions and to review the
overall health of the baby. The clinician discussed the safety con-
cerns of the protocol team (unknown risks of product use in
pregnancy) and invited the participant to describe the thinking
behind her decisions. The participant appeared embarrassed and
anxious during the discussion and went to great lengths to
express her remorse, apologising profusely and disclosing that
she knew she was pregnant before she was screened. She then
also disclosed substituting her urine samples at clinic visits with
samples she had obtained earlier in the day from a person at her
home that she knew would be negative. She described taking
the urine sample container to the ablution facilities and decant-
ing the sample she brought from home into the container and
presenting this to the staff for testing. She said that the preg-
nancy had been unplanned, and that her partner was angry and
threatened infidelity. Consequently, she perceived her risk for
HIV acquisition as high and judged ongoing gel usage to be
essential to her remaining HIV negative. She resorted to hiding
her knowledge of her pregnancy from trial staff, denying symp-
toms and substituting urine samples. She reported adherence to
the gel regimen and that she had not shared gel with anyone
else. She was aware of all the risks related to procedures and
STI medication but said that her desire to prevent HIV acquisi-
tion had overruled these considerations.
Based on the root cause analysis and her disclosure, the par-
ticipant was counselled and excluded from further participation
in the trial, in consultation with CAPRISA’s bioethics head, on
the grounds that she no longer met inclusion criteria for the
study. The case was also reported to the local REC which raised
concerns about the site’s failure to detect a pregnancy of
>12 weeks at screening. The case was also discussed with all
clinical project staff to raise awareness, as well as with the
Community Research Support Group, who supported the deci-
sion to exit the participant from the trial.
DISCUSSION
Among the many possible influences that impact on motivation
to participate in clinical trials,7–13 the desire to access a
restricted but proven HIV prevention method, in the light of
self-perceived increased risk for HIV acquisition, prompted this
participant to misrepresent her true medical status and substitute
her urine sample. She was subsequently exposed to products
and procedures not approved for use in pregnancy with poten-
tial to harm herself and her fetus. The Microbicide Trials
Network has since shown a reassuring safety profile for tenofo-
vir gel both in early and late pregnancy,22 but this information
was unavailable at the time.
Devine et al8 hypothesise that compensation may influence
willingness to tolerate risk, but that this is more likely in those
who participate for financial reward (paid inducement) only.
Macklin14 notes that whether an inducement is considered
undue or not, is entirely subjective and based on the individual’s
value scheme. An empirical assessment of whether moderate
payments are undue in clinical trials also concluded that while
higher payment motivates participation, there was no evidence
that commonly used payments constituted undue inducement.
Higher payments, in contrast, have been found to be less influ-
ential among poorer participants, but this omits consideration
of other factors such as protective benefits and ancillary care.23
In CAPRISA 008, the National Health Research Ethics Council
guideline of 2012 was applied, reimbursing participants fairly
for time, travel and inconvenience,24 which was accepted by the
local REC as not undue. The REC however could not anticipate
the peculiarities of this participant, whose focus was on access
to proven HIV-protective benefits of the study gel through
CAPRISA 008, and not a financial incentive. The fact that the
participant concealed her pregnancy so actively from the site
staff suggests that she knew and understood the study exclusion
criteria, and probably other risk information, well, as a result of
the consent process and her prior participation in CAPRISA
004. There was no proof that she sold the gel for financial gain.
In studies with the prospect of direct benefit through experi-
mental treatment of a disease, participants motivated solely by
financial interests rather than altruism may fabricate symptoms
or intentionally self-harm in order to qualify for the study.8
Participants in HIV prevention efficacy trials do not have a
disease per se, but do have high risk for HIV acquisition, and
would thus benefit directly from an effective experimental pre-
vention product.2 In addition, healthy participants are more
likely to have financial reward as the primary motivator for par-
ticipation, especially those with a low monthly income and low
education.12 Notably, all of the women in this trial shared
characteristics related to high risk for HIV acquisition, including
structural drivers of risk.1 Some women, when approached,
reported pregnancy and refused participation, hence the offer of
prevention to mitigate risk alone, cannot be considered undue
for this sample in general.
In considering the reasons for this participant’s choices, we
should take into account her vulnerability to HIV acquisition
Table 1 CAPRISA 008, consecutive monthly clinical parameters for participant, April 2013 to July 2013, eThekwini Clinical Research Site
*Visit/date Screening Enrolment Visit 1.0 Visit 2.0 Visit 3.0 Visit 3.1† Visit 4.0
Body mass index 23.7 23.7 23.7 24.1 25.0 N/A 26.3
Waist circumference (cm) 79 79 79 79 79 N/A 82
Urine pregnancy test results Negative Negative Negative Negative Negative N/A Negative
Gels dispensed N/A 10 20 20 20 20 Product held
Gels returned used N/A N/A 10 20 20 20 20
Contraception DMPA given N/A N/A N/A DMPA given N/A N/A
*Physical and pelvic examinations are symptom directed and not mandated by the protocol at the monthly follow-up visits.
†Interim visit: participant returned to request additional gel as she was going on holiday with her partner.
CAPRISA, Centre for the AIDS Programme of Research in South Africa; DMPA, depot medroxyprogesterone acetate.
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due to several possible structural predisposing factors, viz. her
poor financial status and consequent dependency on her partner
exacerbated by an unplanned pregnancy, the risk of intimate-
partner violence, inability to negotiate condom usage, especially
during pregnancy and the direct personal benefit of access to
HIV prevention and ancillary care. The combination of these
factors may potentially have constituted, for this participant, an
undue inducement, distinguished here from a paid incentive
which does not always equal willingness to accept risk.14 15
Complicating this further is the variability among volunteers in
their willingness to subject themselves to risk.14 In support of
her motivation to access HIV prevention care is data on motiv-
ation for joining HIV vaccine efficacy trials: 56% of participants
joined to reduce risk and 46% to get protection from HIV, with
female participants more motivated to join for the latter.9 Other
factors, such as altruism, financial payments7–13 cannot be ruled
out as coincidental dynamics that were not closely evaluated in
this atypical case.
This participant was offered a desirable good (tenofovir gel),
as were all participants who enrolled in this post-trial access
trial. Her unique circumstances of suspected partner unfaithful-
ness, poor financial status, perception of increased risk for HIV
acquisition and lack of access to effective HIV prevention
therapy in the public domain may have made the offer appear
excessively good in her specific context and difficult to resist.
She concealed her medical status and substituted her urine
samples in order to be enrolled, potentially placing her fetus at
risk of serious harm through exposure to unapproved proce-
dures and medication.
In our analysis of this case, it is argued that access to the
study product did not constitute an undue inducement because
inducements typically concern only financial incentives. Her
wish to remain protected against HIV was entirely rational and
consistent with the overall purpose of the study, even though
she violated specific study conditions of which she seems to
have been fully aware and took deliberate steps to conceal.
Furthermore, product safety had already been partially estab-
lished by the prior study (CAPRISA 004), but not for preg-
nancy; this may have influenced her risk assessment.
Furthermore, the fact that a single participant engaged in decep-
tion to retain access to study product does not necessarily prove
that the study team and the REC’s appraisal of the incentives
and risk/benefit balance was flawed for the study in general.
RECOMMENDATIONS
The case reviewed in this paper supports the following pertinent
recommendations:
General:
1. Increase awareness among researchers and staff, RECs and
society, of the multiple motivations for participation in post-
trial access trials or substudies, and the limitations of REC
review.
2. Study benefits may be perceived differently among partici-
pants and that focussing on paid inducements and risk/
benefit factors is required.
Specific to trial design:
1. Pregnancy testing methods should not rely only on partici-
pant sample collection, for example, serum pregnancy
testing.
2. Clinician-driven baseline assessments in post-trial access
studies should be used to determine eligibility.
3. Weight and height measurements should be conducted in
procedure rooms where privacy is guaranteed, rather than in
group areas where participants are less inclined to disrobe
appropriately.
4. Collection of real-time genital samples should be done to
determine exposure to study product when safety concerns
arise.
5. Study nurses require advanced training in pregnancy evalu-
ation where pregnancy is an exclusion criterion.
These recommendations should be considered on an individ-
ual study level taking into account human and financial resource
constraints, length of study visits, study design and the likeli-
hood of the occurrence of similar cases.
CONCLUSION
Women in LMICs are challenged by poor socioeconomic status,
gender inequity, high pregnancy rates, increased risk of heterosex-
ual transmission of HIV and variable access to and quality of
healthcare. In a region where an increasing number of prevention
studies are being conducted, other cases of perceived undue
inducement, such as this one, may arise. The risk to safety negates
ignoring participant deception in favour of a moral duty that
recognises peculiarities in a participant’s lived experience. The
drive instead should be to rapidly test proven effective products in
pregnant women25 to ensure equitable access to proven therapies
even in post-trial access studies. The likelihood of any research
team being able to impact the structural drivers of HIV risk as they
pertain to individual participants during a study is low, but recog-
nition of these factors can increase vigilance and application of the
above recommendations to study design and conduct.
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